B-intervention	0	10	Resistance
I-intervention	11	19	training
O	20	28	improves
B-condition	29	36	fatigue
I-condition	37	40	and
I-condition	41	48	quality
I-condition	49	51	of
I-condition	52	56	life
O	57	59	in
O	60	70	previously
O	71	80	sedentary
O	81	87	breast
O	88	94	cancer
O	95	104	survivors
O	104	105	:
O	106	107	a
O	108	118	randomised
O	119	129	controlled
O	130	135	trial
O	135	136	.

O	137	140	The
O	141	148	primary
O	149	152	aim
O	153	155	of
O	156	160	this
O	161	166	study
O	167	170	was
O	171	173	to
O	174	182	evaluate
O	183	186	the
O	187	195	benefits
O	196	198	of
O	199	209	resistance
O	210	218	training
O	219	220	(
O	220	222	RT
O	222	223	)
O	224	226	on
O	227	234	quality
O	235	237	of
O	238	242	life
O	243	244	(
O	244	247	QOL
O	247	248	)
O	249	252	and
O	253	260	fatigue
O	261	263	in
O	264	270	breast
O	271	277	cancer
O	278	287	survivors
O	288	290	as
O	291	293	an
O	294	301	adjunct
O	302	304	to
O	305	310	usual
O	311	315	care
O	315	316	.

O	317	319	We
O	320	329	recruited
B-total-participants	330	332	39
B-eligibility	333	338	women
I-eligibility	339	342	who
I-eligibility	343	346	had
I-eligibility	347	355	survived
I-eligibility	356	362	breast
I-eligibility	363	369	cancer
O	370	371	[
O	371	375	mean
B-age	376	379	age
I-age	380	381	(
I-age	381	382	y
I-age	382	383	)
I-age	384	386	51
I-age	386	387	.
I-age	387	388	9
I-age	389	390	±
I-age	391	392	8
I-age	392	393	.
I-age	393	394	8
O	394	395	;
O	396	400	time
O	401	406	since
O	407	416	diagnosis
O	417	418	(
O	418	419	m
O	419	420	)
O	421	423	11
O	423	424	.
O	424	425	6
O	426	427	±
O	428	430	13
O	430	431	.
O	431	432	2
O	432	433	]
O	433	434	.

O	435	442	Primary
O	443	451	outcomes
O	452	456	were
B-outcome-Measure	457	464	fatigue
O	465	467	as
O	468	476	assessed
O	477	479	by
O	480	483	the
O	484	494	Functional
O	495	505	Assessment
O	506	508	of
O	509	516	Chronic
O	517	524	Illness
O	525	532	Therapy
O	533	534	-
O	535	542	Fatigue
O	543	544	(
O	544	549	FACIT
O	549	550	)
O	551	556	scale
O	557	560	and
B-outcome-Measure	561	564	QOL
O	565	567	as
O	568	576	assessed
O	577	579	by
O	580	583	the
O	584	594	Functional
O	595	605	Assessment
O	606	608	of
O	609	615	Cancer
O	616	623	Therapy
O	624	625	-
O	626	633	General
O	634	635	(
O	635	639	FACT
O	639	640	-
O	640	641	G
O	641	642	)
O	643	648	scale
O	648	649	.

O	650	656	ANCOVA
O	657	660	was
O	661	665	used
O	666	668	to
O	669	675	assess
O	676	679	the
O	680	686	change
O	687	689	in
O	690	693	the
O	694	701	primary
O	702	710	outcomes
O	711	716	while
O	717	728	controlling
O	729	732	for
O	733	741	baseline
O	742	748	values
O	748	749	,
O	750	754	with
O	755	761	effect
O	762	767	sizes
O	768	769	(
O	769	771	ES
O	771	772	)
O	773	782	displayed
O	783	785	as
O	786	793	partial
O	794	797	Eta
O	798	805	squared
O	805	806	.

O	807	810	The
O	811	823	experimental
O	824	829	group
O	830	838	received
O	839	849	supervised
O	850	852	RT
O	853	854	3
O	855	859	days
O	860	863	per
O	864	868	week
O	869	871	in
O	872	873	a
O	874	884	university
O	885	891	clinic
O	892	895	for
O	896	898	16
O	899	904	weeks
O	904	905	.

B-outcome	906	917	Perceptions
I-outcome	918	920	of
I-outcome	921	928	fatigue
O	929	937	improved
O	938	951	significantly
O	952	954	in
O	955	958	the
O	959	961	RT
O	962	967	group
O	968	976	compared
O	977	979	to
B-control	980	988	controls
O	989	990	[
O	990	994	mean
O	995	996	(
O	996	998	SD
O	998	999	)
B-iv-cont-mean	1000	1001	6
I-iv-cont-mean	1001	1002	.
I-iv-cont-mean	1002	1003	7
O	1004	1005	(
B-iv-cont-sd	1005	1006	7
I-iv-cont-sd	1006	1007	.
I-iv-cont-sd	1007	1008	5
O	1008	1009	)
O	1010	1016	points
O	1017	1019	vs
O	1019	1020	.
B-cv-cont-mean	1021	1022	1
I-cv-cont-mean	1022	1023	.
I-cv-cont-mean	1023	1024	5
O	1025	1026	(
B-cv-cont-sd	1026	1027	3
I-cv-cont-sd	1027	1028	.
I-cv-cont-sd	1028	1029	7
O	1029	1030	)
O	1031	1037	points
O	1037	1038	]
O	1038	1039	,
O	1040	1041	(
O	1041	1042	P
O	1043	1044	=
O	1045	1046	0
O	1046	1047	.
O	1047	1050	006
O	1050	1051	,
O	1052	1054	ES
O	1055	1056	=
O	1057	1058	0
O	1058	1059	.
O	1059	1061	20
O	1061	1062	)
O	1063	1065	as
O	1066	1069	did
B-outcome	1070	1073	QOL
O	1074	1075	[
B-iv-cont-mean	1075	1076	6
I-iv-cont-mean	1076	1077	.
I-iv-cont-mean	1077	1078	9
O	1079	1080	(
B-iv-cont-sd	1080	1081	8
I-iv-cont-sd	1081	1082	.
I-iv-cont-sd	1082	1083	5
O	1083	1084	)
O	1085	1091	points
O	1092	1094	vs
O	1094	1095	.
B-cv-cont-mean	1096	1097	1
I-cv-cont-mean	1097	1098	.
I-cv-cont-mean	1098	1099	6
O	1100	1101	(
B-cv-cont-sd	1101	1102	4
I-cv-cont-sd	1102	1103	.
I-cv-cont-sd	1103	1104	4
O	1104	1105	)
O	1106	1112	points
O	1112	1113	]
O	1113	1114	,
O	1115	1116	(
O	1116	1117	P
O	1118	1119	=
O	1120	1121	0
O	1121	1122	.
O	1122	1125	015
O	1125	1126	,
O	1127	1129	ES
O	1130	1131	=
O	1132	1133	0
O	1133	1134	.
O	1134	1136	16
O	1136	1137	)
O	1137	1138	.

O	1139	1141	We
O	1142	1154	demonstrated
O	1155	1159	both
O	1160	1173	statistically
O	1174	1177	and
O	1178	1188	clinically
O	1189	1198	important
O	1199	1211	improvements
O	1212	1214	in
O	1215	1222	fatigue
O	1223	1226	and
O	1227	1230	QOL
O	1231	1233	in
O	1234	1242	response
O	1243	1245	to
O	1246	1248	RT
O	1249	1251	in
O	1252	1258	breast
O	1259	1265	cancer
O	1266	1275	survivors
O	1275	1276	.
